medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-7-46-50medalphabet-1997Research ArticleОНКОЛОГ - ТЕРАПЕВТУПодходы к лечению COVID19 с позиции коррекции эндотелиопатии и профилактики тромботических осложненийApproaches to treatment of COVID19 from perspective of correction of endotheliopathy and prevention of thrombotic complicationshttps://orcid.org/0000-0001-8975-8608ВёрткинА. Л.VertkinA. L.

Вёрткин Аркадий Львович, д.м.н., проф., зав. кафедрой терапии, клинической фармакологии и скорой медицинской помощи. eLibrary.ru SPIN: 9605–9117

Москва

Vertkin Arkady L., DM Sci, prof., head of Department of Therapy, Clinical Pharmacology and Emergency Medicine

Moscow

kafedrakf@mail.ruhttps://orcid.org/0000-0003-3606-3823ЗайратьянцО. В.ZayratyantsO. V.

Олег Вадимович Зайратьянц, д.м.н., проф., заслуженный врач России, зав. кафедрой патологической анатомии. eLibrary.ru SPIN: 4817–1084

Москва

Zayratyants Oleg V., DM Sci, prof., head of Department of Pathological Anatomy

Moscow

ovzair@mail.ruФГБОУ ВО «Московский государственный медико-стоматологический университет имени А .И. Евдокимова» Минздрава РоссииРоссияMoscow State University of Medicine and Dentistry n.a. A. I. EvdokimovRussian Federation20210606202107Современная поликлиника (1)4650Copyright © Вёрткин А.Л., Зайратьянц О.В., 20212021Вёрткин А.Л., Зайратьянц О.В.Vertkin A.L., Zayratyants O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/1997

Пандемия новой коронавирусной инфекции COVID‑19, согласно данным последних исследований, имеет в своем патогенезе значимое влияние на сосудисто-тромбоцитарный гемостаз. Статья рассматривает тактику ведения пациентов с COVID‑19 с позиций оценки нарушений гемостаза, рисков тромбообразования и коррекция выявляемых нарушений.

The pandemic of the new coronavirus infection COVID‑19, according to recent studies, has a significant effect on vascular platelet hemostasis in its pathogenesis. The article examines the tactics of managing patients with COVID‑19 from the standpoint of assessing hemostasis disorders, the risks of thrombus formation and the correction of detected disorders.

new coronavirus infectionCOVID‑19vascular-platelet hemostasishemostasisglycocalyxsulodexideReferencesWiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID 19): A Review. JAMA. 2020; 324 (8) 782–793. DOI: 10.1001/jama.2020.12839.Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID 19): A Review. JAMA. 2020; 324 (8) 782–793. DOI: 10.1001/jama.2020.12839.Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID 19 coronavirus (SARS-CoV 2) – an update on the status. Infect Genet Evol. 2020; 83: 104327. https://doi.org/10.1016/j.meegid.2020.104327Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID 19 coronavirus (SARS-CoV 2) – an update on the status. Infect Genet Evol. 2020; 83: 104327. https://doi.org/10.1016/j.meegid.2020.104327Зайратьянц О.В., Самсонова М.В., Михалева Л.М., Черняев А.Л., Мишнев О.Д., Крупнов Н.М., Калинин Д.В. Патологическая анатомия COVID 19: Атлас. Под общей ред. Зайратьянца О.В. М.: ГБУ «НИИОЗММ ДЗМ»; 2020.Zajrat’yants OV, Samsonova MV, Mihaleva LM, Chernyaev AL, Mishnev OD, Krupnov NM, Kalinin DV. Pathological Anatomy of COVID 19: Atlas. Ed. Zajrat’yants O.V. M.: GBU «NIIOZMM DZM»; 2020 (In Russ.).Верткин А.Л., Зайратьянц О.В., Кебина А.Л., Сычева А.С., Куандыкова М.В., Носова А.В., Красненкова С.Ф., Астахова О.И., Завьялов Г.В. Клинические маски COVID 19: клиникоморфологические сопоставления. Терапия. 2020. Т. 6; № 7 (41): 102–112.Vertkin A. L., Zayratyants O.V., Kebina A. L., Sycheva A. S., Kuandykova M.V., Nosova A.V., Krasnenkova S.F., Astakhova O.I., Zavyalov G.V. COVID 19 clinical maskings: clinical and morphological comparisons. Therapy. 2020; 7: 102–112. (In Russian). DOI: 10.18565/therapy.2020.7.102–112.Временные методические рекомендации профилактика, диагностика и лечение новой коронавирусной инфекции (COVID 19). Министерство здравоохранения РФ. Версия 9. (Ссылка активна на 03.03.21.) https://static 0.minzdrav.gov.ru/system/attachments/attaches/000/052/550/original/%D0%9C%D0%A0_COVID 19_%28v9%29.pdf?1603788097Interim guidelines for the prevention, diagnosis and treatment of novel coronavirus infection (COVID 19). Ministry of Health of the Russian Federation. Version 9. (Link active on 03.03.21) (In Russ.). https://static 0.minzdrav.gov.ru/system/attachments/attaches/000/052/550/original/%D0%9C%D0%A0_COVID 19_%28v9%29.pdf?1603788097Maugeri et al., Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparin. Haematologica 2005 90 (6): 833–9.Maugeri et al., Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparin. Haematologica 2005 90 (6): 833–9.Maugeri N et al. Parnaparin, a low-molecular-weight heparin, prevents P-selectin dependent formation of platelet-leukocyte aggregates in human whole blood. Thromb Haemost 2007; 97: 965–973.Maugeri N et al. Parnaparin, a low-molecular-weight heparin, prevents P-selectin dependent formation of platelet-leukocyte aggregates in human whole blood. Thromb Haemost 2007; 97: 965–973.Черняховская Н.Е., Шишло В.К., Поваляев А.В. Коррекция микроциркуляции в клинической практике. М.: Бином, 2013. 208 с.Chernyahovskaya NE, Shishlo VK, Povalyaev AV. Correction of microcirculation in clinical practice. Moscow: Binom, 2013. 208 p. (In Russ.).Кузнецова И.В. Роль преконцепционной эндотелиальной дисфункции в развитии акушерских осложнений. Медицинский алфавит. 2019; 1 (1): 53–58. DOI: 10.33667/2078–5631–2019–1–1(376)-53–58.Kuznetsova IV. Role of preconception endothelial dysfunction in development of obstetric complications. Medical alphabet. 2019; 1 (1): 53–58. (In Russ.) DOI: 10.33667/2078–5631–2019–1–1(376)-53–58.Kssja RJ, Greer IA. Manifestations of chronic disease during pregnancy. JAMA 2005; 294: 2751–2757.Kssja RJ, Greer IA. Manifestations of chronic disease during pregnancy. JAMA 2005; 294: 2751–2757.Mosca L, et al. Effectiveness-based guidelines for the prevention of CVD in women 2011 update. A guideline from the American Heart Association Circulation 2011; 123 (11): 1243–62.Mosca L, et al. Effectiveness-based guidelines for the prevention of CVD in women 2011 update. A guideline from the American Heart Association Circulation 2011; 123 (11): 1243–62.Masola V, Zaza G, Onisto M, Lupo A, Gambaro G. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014 Jun; 33 (3): 243–54. PMID: 24936533.Masola V, Zaza G, Onisto M, Lupo A, Gambaro G. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014 Jun; 33 (3): 243–54. PMID: 24936533.Endermann D.H. Endothelial Dysfunction. Journal of the American Society of Nephrology. 2004; 15 (8): 1983–1992.Endermann D.H. Endothelial Dysfunction. Journal of the American Society of Nephrology. 2004; 15 (8): 1983–1992.Schutte A, Harrison D. Immunity, inflammation and the vasculature in the COVID 19 era. J. of hypertension, Sep 2020. Vol. 38, No. 9, pp. 1701–1702.Schutte A, Harrison D. Immunity, inflammation and the vasculature in the COVID 19 era. J. of hypertension, Sep 2020. Vol. 38, No. 9, pp. 1701–1702.Moore J., June C. Cytokine release syndrome in severe COVID 19. Science, May 1, 2020. Vol. 368, No. 6490, pp. 473–474.Moore J., June C. Cytokine release syndrome in severe COVID 19. Science, May 1, 2020. Vol. 368, No. 6490, pp. 473–474.Ackermann M., Verleden S., Kuehnel M. et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid 1. N Engl J Med 2020; 383: 120–128. DOI: 10.1056/NEJMoa2015432.Ackermann M., Verleden S., Kuehnel M. et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid 1. N Engl J Med 2020; 383: 120–128. DOI: 10.1056/NEJMoa2015432.Becker B., Jacob M., Leipert S., Salmon A., Chappell D. Degradation of theendothelial glycocalyx in clinical settings: searching forthe sheddase. Br J Clin Pharmacol, March 16, 2015. Vol. 80, No. 3, pp. 389–402.Becker B., Jacob M., Leipert S., Salmon A., Chappell D. Degradation of theendothelial glycocalyx in clinical settings: searching forthe sheddase. Br J Clin Pharmacol, March 16, 2015. Vol. 80, No. 3, pp. 389–402.Evans P., Rainger G., M. J, Guzik T., Osto E., Stamataki Z. and e. al. Endothelial dysfunction in COVID 19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovasc Res. 2020 Dec 1; 116 (14): 2177–2184. DOI: 10.1093/cvr/cvaa230.Evans P., Rainger G., M. J, Guzik T., Osto E., Stamataki Z. and e. al. Endothelial dysfunction in COVID 19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovasc Res. 2020 Dec 1; 116 (14): 2177–2184. DOI: 10.1093/cvr/cvaa230.Cao R., Tang L., Xia Z., Xia R. Endothelial glycocalyx as a potential theriapeutic target in organ injuries. Chin Med J (Engl). 2019 Apr 20; 132 (8): 963–975.Cao R., Tang L., Xia Z., Xia R. Endothelial glycocalyx as a potential theriapeutic target in organ injuries. Chin Med J (Engl). 2019 Apr 20; 132 (8): 963–975.Верткин А.В., Авдеев С.Н., Ройтман Е.В., Сучков И.А., Кузнецова И.В., Замятин М.Н., Стойко Ю.М., Журавлева М.В., Зайратьянц О.В. Вопросы лечения COVID 19 с позиции коррекции эндотелиопатии и профилактики тромботических осложнений. Согласованная позиция экспертов. Профилактическая медицина. 2021; 24 (4): 45–51. https://doi.org/10.17116/profmed20212405145Vertkin AL, Avdeev SN, Roitman EV, Suchkov IA, Kuznetsova IV, Zamyatin MN, Stoiko YuM, Zhuravleva MV, Zayratyants OV. Treatment of COVID 19 from the perspective of endotheliopathy correction and prevention of thrombotic complications. The agreed position of the experts. The Russian Journal of Preventive Medicine. 2021; 24 (4): 45–51. (In Russ.) https://doi.org/10.17116/profmed20212405145Walenga JM, Fareed J, Ramacciotti E. Sulodexide for the extended treatment of venous thromboembolism. Int Angiol. 2016 Dec; 35 (6): 531–533.Walenga JM, Fareed J, Ramacciotti E. Sulodexide for the extended treatment of venous thromboembolism. Int Angiol. 2016 Dec; 35 (6): 531–533.Broekhuizen L.N., Lemkes B.A., Mooij H. L. et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010; 53 (12): 2646–2655.Broekhuizen L.N., Lemkes B.A., Mooij H. L. et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010; 53 (12): 2646–2655.Mannello F., Ligi D., Сanale M. and Raffetto J. Sulodexide Down-Regulates the Release of Cytokines, Chemokines, and Leukocyte Colony Stimulating Factors from Human Macrophages: Role of Glycosaminoglycans in Inflammatory Pathways of Chronic Venous. Current Vascular Pharmacology, 2014; 12 (1): 173–85. DOI: 10,2174/1570161111666131126144025.Mannello F., Ligi D., Сanale M. and Raffetto J. Sulodexide Down-Regulates the Release of Cytokines, Chemokines, and Leukocyte Colony Stimulating Factors from Human Macrophages: Role of Glycosaminoglycans in Inflammatory Pathways of Chronic Venous. Current Vascular Pharmacology, 2014; 12 (1): 173–85. DOI: 10,2174/1570161111666131126144025.Gonzalez-Ochoa A. J., Raffetto J.D., Hernández A.G., et al. Sulodexide in the treatment of patients with early stages of COVID 19: a randomised controlled trial. medRxiv 2020.12.04. 20242073. DOI: https://doi.org/10.1101/2020.12.04.20242073Gonzalez-Ochoa A. J., Raffetto J.D., Hernández A.G., et al. Sulodexide in the treatment of patients with early stages of COVID 19: a randomised controlled trial. medRxiv 2020.12.04. 20242073. DOI: https://doi.org/10.1101/2020.12.04.20242073Giuseppe M. Andreozzi, Angelo A. Bignamini, Giovanni Davì, Gualtiero Palareti, Jiří Matuška, Martin Holý, Katarzyna Pawlaczyk-Gabriel, Andrej Džupina, German Y. Sokurenko The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial, Circulation. 2015; 132: 1891–1897. DOI: 10.1161/CIRCULATIONAHA.115.016930.Giuseppe M. Andreozzi, Angelo A. Bignamini, Giovanni Davì, Gualtiero Palareti, Jiří Matuška, Martin Holý, Katarzyna Pawlaczyk-Gabriel, Andrej Džupina, German Y. Sokurenko The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial, Circulation. 2015; 132: 1891–1897. DOI: 10.1161/CIRCULATIONAHA.115.016930.Золотницкая В.П., Кузубова Н.А., Титова О.Н. и др. Возможности коррекции капиллярного кровообращения в легких у пациентов с хронической обструктивной болезнью легких с сочетанной патологией. Пульмонология. 2017; 27 (6): 767–775. DOI: 10.18093/0869–0189–2017–27–6–767–775.Zolotnitskaya VP, Kuzubova NA, Titova ON, Surkova EA, Shumilov AA. An opportunity to improve pulmonary capillary circulation in patients with chronic obstructive pulmonary disease and comorbidity. Pulmonologiya. 2017; 27 (6): 767–775. (In Russ.) DOI: 10.18093/0869–0189–2017–27–6–767–775.Шевченко Ю.Л., Стойко Ю.М., Гудымович В.Г., Черняго Т.Ю. Гликокаликс – определяющий фактор в развитии эндотелиальной дисфункции при венозной патологии и возможности ее коррекции. Ангиология и сосудистая хирургия. 2020; 26 (4): 71–76.Shevchenko YuL, Stojko YuM, Gudymovich VG, Chernyago TYu. Glycocalyx as a determining factor in the development of endothelial dysfunction in venous pathology and the possibility of its correction. Angiology and Vascular Surgery. (In Russ.)Рекомендации МГНОТ по диагностике и интенсивной терапии синдрома диссеминированного внутрисосудистого свертывания крови при вирусном поражении легких. Под редакцией Воробьева П.А. и Елыкомова В.А. Проблемы стандартизации в здравоохранении. 2020; 5–6. DOI: 10.26347/1607–2502202005–06099–111.MGNOT recommendations for the diagnosis and intensive care of disseminated intravascular coagulation syndrome in viral lung disease. Edited by P.A. Vorobyov and Elykomova V. A. Problems of standardization in healthcare. 2020; 5–6. DOI: 10.26347/1607–2502202005–06099–111.

The authors declare that there are no conflicts of interest present.